(Reuters) – Certain genes may identify patients with obesity who are most likely to respond strongly to Novo Nordisk’s weight-loss drug Wegovy, researchers reported on Monday.
The study, presented at the Digestive Disease Week in Washington, demonstrated a 95% likelihood of a strong treatment response. Researchers identified patients with this genetic profile.
Dr. Andres Acosta from the Mayo Clinic suggests using the findings to pinpoint patients who are likely to benefit the most. Identifying crucial patients is imperative due to Wegovy’s cost.
Some people with obesity have a genetic profile that contributes to what is called a “hungry gut” – that is, they feel full during a meal but become hungry again shortly afterward because food leaves their stomach more quickly than in most other people, Acosta said.
The study involved 84 patients prescribed Wegovy for treatment of obesity. Those with the genetic variants associated with “hungry gut” lost an average of 14.4% of their total body weight after nine months on the drug and 19.5% after a year, the study found.
By comparison, study participants without this genetic profile lost 10.3% of their body weight after nine months and nothing more by 12 months.
Moreover, integrating genetic testing into weight-loss programs can streamline the treatment process. Patients can undergo genetic testing to determine their suitability for Wegovy. Once the genetic profile is established, healthcare providers can tailor the weight-loss plan accordingly. This proactive approach not only saves time but also enhances patient confidence and satisfaction.
The focus on Wegovy genetic response underscores the importance of personalized medicine in achieving long-term weight loss success. Ultimately, leveraging genetic information can transform the weight-loss journey, offering hope and effective solutions to those struggling with obesity.
read more
image source
